ARPEGGIO · TV5600-CNS-20006
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of once-daily oral laquinimod (0.6 or 1.5 mg) in patients with primary progressive multiple sclerosis. EudraCT: 2014-001579-30
Sponsor: TEVA
Phase: II
Area: Neuroimmunology